Predicting Atrial Fibrillation Recurrence Using Inflammatory Markers and Gene Scores A Study of Adults With Persistent Atrial Fibrillation Undergoing Electrical Cardioversion

What this Trial Is About

Researchers are studying patients with persistent atrial fibrillation who are planned for electrical cardioversion to evaluate how inflammatory markers and gene scores may predict the recurrence of atrial fibrillation after this procedure. The study focuses on identifying better prediction models by examining a broader set of inflammatory indexes beyond those already studied, such as high-sensitivity CRP, CRP, and IL-6. This observational prospective cohort study is led by Vrinnevi Hospital and aims to improve understanding of factors related to atrial fibrillation recurrence. Participants will have blood samples drawn before electrical cardioversion and at several follow-up points 7, 30, 90, and 180 days after the procedure. This allows researchers to monitor changes in biomarkers and gene expression over time. The study involves collecting data through blood sampling only, with no experimental treatments administered. An interim analysis will be performed after including more than 80 patients to assess the significance of the findings. During the study, recurrence of atrial fibrillation will be tracked through 12-lead ECGs conducted at follow-up visits or when symptoms occur. Researchers will also observe fluctuations in inflammatory and genetic markers during the follow-up period. Participants can expect regular follow-up visits for blood sampling and heart rhythm monitoring over six months. The total duration of participation extends from the initial cardioversion through the 180-day follow-up, with ongoing assessment of heart rhythm and biomarker levels.

Impact of Inflammatory Indexes and Gene Scores in Prediction of Atrial Fibrillation